Praxis Precision Medicines, Inc. (NASDAQ:PRAX) is one of the best stocks to buy and hold for the next 6 months. On February ...
Praxis Precision Medicines, Inc. PRAX reported a wider-than-expected loss for the fourth quarter on Thursday. The company posted quarterly losses of $3.50 per share which missed the analyst consensus ...
Two new drug applications (NDA) for ulixacaltamide in essential tremor (ET) and for relutrigine in SCN2A and SCN8A developmental and epileptic ...
7d
How Investors Are Reacting To Praxis (PRAX) Advancing Breakthrough NDA Plans With a 2028 Cash Runway
Praxis Precision Medicines recently presented at Guggenheim’s Emerging Outlook: Biotech Summit 2026 and outlined plans to submit New Drug Applications for ulixacaltamide and relutrigine, both of which ...
Praxis Precision Medicine (NASDAQ: PRAX) reported its Q4 earnings results on Thursday, February 19, 2026 at 07:30 AM. Here's ...
The consensus estimate for Q4 2025 revenue is $0.04 million, and the earnings are expected to come in at -$3.08 per share. The full year 2025's revenue is expected to be $0.04 million and the earnings ...
The Company will host a conference call and a live webcast to review the fourth quarter financial results and provide a corporate update on Thursday, February 19, 2026, at 8:00 am ET, which can be ...
Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results